Michel Rivier Email & Phone Number

Passionate about addressing unmet medical needs through sound science and innovation to create solutions for patients and value for companies. Currently focused on delivering support to emerging biotechs through a Virtual Incubator at Syneos Health: assist partners in building their strategies, identifying the most attractive clinical indications by balancing science and market requirements, establishing early risk mitigation, and positioning realistic value inflection points to improve funding opportunities and accelerate projects while preserving their value.Over than 25 years of experience in drug development for the pharmaceutical and CRO industries in worldwide Prescription, covering all aspects of drug development ranging from discovery, non-clinical Pharmacology, Pharmacokinetics, early clinical proof-of-concept development up to registration (USA/EMEA) and life cycle management. Strong Biomedical background and experience in Translational Sciences and Precision Medicine. Proven ability through several positions to lead cross-functional teams in a multi-cultural environment.Key achievements include:Jan 2023: Successful submission and approval of an IND for a bispecific conditional antibody targeting solid tumors in oncology.2021: Creation and implementation of the Syneos Preclinical Virtual Incubator-Accelerator, a unique model and commercial offering dedicated to emerging biotech, to bring their assets to the clinical stage as quickly as possible.2020: As a business developer, expansion of the client portfolio by building strong relationships with key decision-makers and identifying new business opportunities.2018: Creation and implementation of a new laboratory dedicated to translational sciences, precision medicine, and biomarkers for Syneos Health (covering areas such as Immunology & Inflammation, General Medicine, Infectious Disease, Immuno-Oncology, Rare Disease, and Diagnostics).2019: Successful leadership in the clinical phase III program and dossier submission of Aklief® with FDA approval (dermatology)2016: Successful leadership in the registration of Epiduo Forte® in Europe (dermatology)2012-2015: Successful nomination of numerous New Chemical Entities and transition of clinical candidates from research to early clinical stages in various indications, including psoriasis and atopic dermatitis.

Listed skills include Biotechnology, Pharmaceutical Industry, Secteur Pharmaceutique, Biotechnologie, and 2 others.

• 

  Université Nice Sophia Antipolis

  Phd, Molecular And Cellular Biology